샘플 요청 목록

 카트 문의
시장보고서
상품코드
1787200

세계의 멀티오믹스 시장

Multiomics
발행일: | 리서치사: Market Glass, Inc. (Formerly Global Industry Analysts, Inc.) | 페이지 정보: 영문 209 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 멀티오믹스 시장 규모는 2030년까지 74억 달러에 달할 전망

세계의 멀티오믹스 시장 규모는 2024년에 29억 달러로 추정되며, 2024-2030년에 CAGR 16.6%로 성장하여 2030년에는 74억 달러에 달할 것으로 예측됩니다. 이 보고서에서 분석한 부문 중 하나인 벌크 멀티오믹스는 CAGR 17.9%를 기록하며 분석 기간 종료시에는 51억 달러에 달할 것으로 예측됩니다. 단일세포 멀티오믹스 부문의 성장률은 분석 기간 CAGR로 14.1%로 추정됩니다.

미국 시장은 7억 6,910만 달러로 추정, 중국은 CAGR 15.6%로 성장 예측

미국의 멀티오믹스 시장은 2024년에 7억 6,910만 달러로 추정됩니다. 세계 2위 경제 대국인 중국은 2030년까지 11억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간 2024-2030년 CAGR은 15.6%를 기록할 것으로 예상됩니다. 기타 주목할 만한 지역 시장으로는 일본과 캐나다가 있고, 분석 기간 동안 CAGR은 각각 15.5%와 14.2%로 예측됩니다. 유럽에서는 독일이 CAGR 약 12.1%로 성장할 것으로 예측됩니다.

세계 멀티오믹스 시장 : 주요 동향 및 촉진요인 개요

멀티오믹스는 생물학적 인사이트와 정밀의료를 어떻게 재정의하고 있는가?

유전체학, 전사체학, 단백질체학, 후성유전체학, 대사체학을 결합한 통합적 접근법인 멀티오믹스는 생물학 연구와 임상 적용에 혁명을 일으키고 있습니다. 멀티오믹스는 여러 생물층에 걸친 방대한 데이터세트를 활용함으로써 복잡한 질병, 생물학적 기능, 맞춤형 의료에 대한 더 깊은 이해를 제공합니다. 시퀀싱 기술과 고처리량 분석 도구의 발전으로 연구자들은 다양한 분자 성분 간의 상호 작용을 전례 없는 정밀도로 조사할 수 있게 되었습니다. 머신러닝과 인공지능의 통합은 멀티오믹스 데이터의 해석을 더욱 가속화하여 바이오마커 발견, 질병 진단 및 치료 개입에 획기적인 발전을 가져오고 있습니다. 종양학에서 멀티오믹스는 종양의 이질성을 밝혀내어 보다 표적화된 치료 요법을 촉진하고 있습니다. 마찬가지로 알츠하이머병이나 파킨슨병과 같은 신경퇴행성 질환에서도 멀티오믹스는 유전적, 대사적 배경을 밝히는 시스템생물학적 접근을 가능하게 합니다. 제약 업계는 신약개발 강화, 임상시험의 계층화 최적화, 치료에 대한 환자 반응 예측을 위해 멀티오믹스를 적극 도입하고 있습니다. 클라우드 컴퓨팅과 첨단 생물정보학 도구의 등장으로 멀티오믹스 데이터를 대규모로 저장, 분석, 해석할 수 있는 능력이 크게 향상되어 전 세계 연구자들이 보다 쉽게 접근할 수 있게 되었습니다. 정부 및 의료 기관들은 중개연구를 가속화할 수 있는 가능성을 인식하고 대규모 멀티오믹스 이니셔티브에 자금을 지원하고 있습니다. 이러한 발전에도 불구하고, 이 분야는 데이터 조화, 표준화, 데이터 공유에 대한 윤리적 고려와 관련된 문제에 직면해 있습니다. 그럼에도 불구하고, 계산생물학과 데이터 통합 프레임워크의 끊임없는 혁신으로 멀티오믹스는 정밀의료와 질병 예방 전략에 변화를 가져올 준비가 되어 있습니다.

멀티오믹스의 혜택을 받을 수 있는 새로운 응용 분야와 산업은?

멀티오믹스는 정밀의료에서의 역할 외에도 농업, 마이크로바이옴 연구, 영양과학, 환경 모니터링 등 다양한 분야에 적용되고 있습니다. 농업 분야에서 멀티오믹스는 작물의 회복력을 높이고, 토양 미생물을 개선하며, 기후 변화로 인한 스트레스 요인을 견딜 수 있는 유전적으로 우수한 식물 품종을 개발하기 위해 활용되고 있습니다. 마이크로바이옴 연구는 인간 건강, 농업, 산업 생명공학의 복잡한 미생물 상호작용 연구에 멀티오믹스를 활용하고 있습니다. 메타유전체, 단백질체학, 대사체학을 장내 세균총 연구에 적용함으로써 장내 미생물 구성과 비만, 당뇨, 염증성 질환 등의 질병과의 연관성을 규명하는 획기적인 발견이 이루어졌습니다. 영양학에서 멀티오믹스는 개인의 유전적, 대사적 프로파일에 따라 개인화된 식단을 추천하는 영양유전체학로의 길을 열어가고 있습니다. 식음료 산업에서는 발효 공정 최적화, 프로바이오틱스 처방 개선, 고급 미생물 프로파일링을 통한 식품 안전성 확보를 위해 멀티오믹스가 활용되고 있습니다. 또한, 멀티오믹스는 생태계의 생물 다양성 모니터링, 오염의 영향 추적, 심해 열수분출구와 같은 극한 환경에서의 미생물 군집 조사 등을 가능하게 하여 환경과학에도 크게 기여하고 있습니다. 독성학 분야에서는 분자 수준에서 화학제품 노출을 이해하기 위해 멀티오믹스 접근법이 점점 더 통합되고 있으며, 위험 평가 및 규제 프레임워크가 개선되고 있습니다. 합성생물학의 발전과 함께 멀티오믹스는 새로운 바이오소재, 바이오연료, 바이오의약품의 엔지니어링을 촉진하고 그 산업적 의미를 더욱 확대시키고 있습니다. 멀티오믹스의 다학제적 채택이 증가하고 있는 것은 전통적인 생물 의학 연구의 틀을 넘어 혁신을 촉진하고 과학 및 상업 부문에 변화를 가져올 수 있는 영향력을 강조하고 있습니다.

멀티오믹스 데이터 통합이 미래의 과학적 혁신에 필수적인 이유는 무엇일까?

멀티오믹스 데이터세트의 통합은 이 분야에서 가장 도전적이면서도 미래지향적인 과제 중 하나입니다. 멀티오믹스 연구에서 생성되는 방대한 양의 데이터는 서로 다른 생물학적 계층을 넘나들며 인사이트를 통합할 수 있는 고급 계산 모델이 필요합니다. 최근 AI 기반 분석, 협업 학습, 네트워크 기반 모델링의 발전은 멀티오믹스 데이터 융합을 개선하고 보다 강력한 바이오마커 발견과 질병 모델링으로 이어지고 있습니다. 데이터 파이프라인의 표준화와 오픈 액세스 리포지토리의 개발로 연구자 간 공동 연구를 촉진하고 메타분석과 집단 간 연구가 가능해졌습니다. 단일세포 멀티오믹스의 출현은 세포의 이질성을 이해하는 해상도를 더욱 높여 면역학, 암 생물학, 발생 생물학에서 유용함을 입증하고 있습니다. 또 다른 획기적인 기술인 공간 멀티오믹스는 연구자들이 조직 내 분자 간 상호작용을 공간적으로 정확하게 매핑하여 질병 병리학에 대한 새로운 인사이트를 제공할 수 있게 해줍니다. 그러나 배치 효과, 재현성 문제, 계산 기반 강화의 필요성 등의 과제가 여전히 보급의 장벽으로 작용하고 있습니다. 다기관 공동 연구와 데이터 공유 프레임워크를 추진함으로써 이러한 문제를 완화하고, 멀티오믹스 조사의 재현성과 투명성을 높일 수 있을 것으로 기대됩니다. 멀티오믹스와 계산 모델이 생물학적 반응을 시뮬레이션하는 디지털 트윈 기술과의 통합도 맞춤형 의료 및 치료 개발에 혁명을 일으킬 수 있는 유망한 분야입니다. 멀티오믹스가 계속 진화하면서 양자 컴퓨터, CRISPR을 이용한 유전자 편집, 바이오프린팅 등 첨단 분야와의 교류가 늘어나면서 과학적 발견에 새로운 길을 열어가고 있습니다. 멀티오믹스 데이터를 원활하게 통합하는 능력은 이 기술의 잠재력을 극대화하고 질병 궤적과 치료 반응을 보다 정확하게 예측할 수 있도록 하는 데 매우 중요합니다.

멀티오믹스 세계 시장 급성장의 원동력은?

세계 멀티오믹스 시장의 성장은 기술 발전, 신약 개발에서의 채택 증가, 오믹스 기반 연구에 대한 자금 지원 증가 등 여러 가지 요인에 의해 주도되고 있습니다. 차세대 시퀀싱(NGS), 질량분석, 하이스루풋 스크리닝 플랫폼의 급속한 개발로 정확도와 확장성이 향상되는 동시에 비용이 크게 절감되었습니다. 제약 및 생명공학 업계는 정밀의료 이니셔티브를 가속화하고, 바이오마커 식별을 강화하며, 임상시험에서 환자 선택을 최적화하기 위해 멀티오믹스에 많은 투자를 하고 있습니다. 암, 자가면역질환, 신경퇴행성 질환 등 복잡한 질환의 발생률이 증가함에 따라 멀티오믹스를 활용한 진단 및 치료제 수요가 더욱 증가하고 있습니다. 멀티오믹스를 인공지능 및 빅데이터 분석과 통합함으로써, 특히 희귀질환 및 맞춤형 헬스케어 솔루션에 초점을 맞춘 연구에 벤처 캐피털과 정부로부터 많은 자금이 유입되고 있습니다. 규제 당국은 의약품의 안전성과 효능을 향상시키는 멀티오믹스의 가치를 점점 더 인식하고 있으며, 이는 오믹스 기반 임상시험과 동반진단을 지원하는 유리한 정책으로 이어지고 있습니다. 소비자 대상 유전자 검사 회사와 맞춤형 건강 프로그램의 등장으로 멀티오믹스 활용의 상업적 전망은 더욱 확대되고 있습니다. 또한, 농업, 식품 안전, 환경 모니터링 분야에서 멀티오믹스에 대한 관심이 높아짐에 따라 인체 건강 이외의 분야에서도 멀티오믹스 도입이 촉진되어 시장 다각화에 기여하고 있습니다. 데이터 분석, 바이오마커 검증, 클라우드 기반 인포매틱스 플랫폼 등 엔드-투-엔드 솔루션을 제공하는 멀티오믹스 서비스 제공업체의 등장으로 멀티오믹스 연구는 학계 연구자뿐만 아니라 산업계 연구자들에게도 더욱 친숙해지고 있습니다. 더 친숙해졌습니다. 멀티오믹스 기술 개발자, 의료 서비스 제공업체, 제약사 간의 전략적 파트너십은 혁신을 촉진하고, 상업화를 가속화하며, 중개 연구 노력을 강화하고 있습니다. 전 세계 헬스케어 산업이 예방적이고 정밀한 치료 모델로 전환하는 가운데, 멀티오믹스는 미래 헬스케어 패러다임에서 필수적인 도구가 될 것으로 보입니다. 멀티오믹스 기술의 끊임없는 발전과 다양한 산업 분야에서의 응용 분야가 증가함에 따라 향후 몇 년 동안 멀티오믹스 시장은 비약적인 성장을 이룰 것으로 예측됩니다.

부문

제품 유형(벌크 멀티오믹스, 단일세포 멀티오믹스), 플랫폼 유형(유전체학 플랫폼, 전사체학 플랫폼, 단백질체학 플랫폼, 대사체학 플랫폼, 통합 오믹스 플랫폼), 용도(종양학 용도, 세포생물학 용도, 신경학 용도, 면역학 용도), 최종 용도(학술·연구기관 최종 용도, 제약·바이오테크놀러지 기업 최종 용도, 기타 최종 용도)

조사 대상 기업 사례

  • 10x Genomics, Inc.
  • Agilent Technologies, Inc.
  • Aitia(전 GNS Healthcare)
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bruker Corporation
  • Danaher Corporation
  • Freenome Holdings, Inc.
  • Human Longevity, Inc.
  • Illumina, Inc.
  • Mission Bio, Inc.
  • NanoString Technologies, Inc.
  • PerkinElmer, Inc.
  • Pleno, Inc.
  • Psomagen, Inc.
  • QIAGEN N.V.
  • Shimadzu Corporation
  • SOPHiA GENETICS
  • Thermo Fisher Scientific Inc.
  • Waters Corporation

AI 통합

Global Industry Analysts는 검증된 전문가 컨텐츠와 AI 툴을 통해 시장 정보와 경쟁 정보를 혁신하고 있습니다.

일반적으로 진행되는 LLM 및 업계 특화형 SLM에 대한 쿼리에 의존하는 대신 우리는 세계 도메인 전문가가 엄선한 컨텐츠를 집약한 리포지토리를 구축했습니다. 여기에는 비디오 녹취록, 블로그, 검색 엔진을 이용한 조사, 방대한 기업 데이터, 제품 및 서비스 정보, 시장 데이터가 포함되어 있습니다.

관세 영향 계수

우리는 본사의 국가, 제조거점, 수출입(완제품과 OEM)에 따른 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수익원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 주요 요약

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 기타 유럽
  • 아시아태평양
  • 기타 지역

제4장 경쟁

KSM 25.08.21

Global Multiomics Market to Reach US$7.4 Billion by 2030

The global market for Multiomics estimated at US$2.9 Billion in the year 2024, is expected to reach US$7.4 Billion by 2030, growing at a CAGR of 16.6% over the analysis period 2024-2030. Bulk Multiomics, one of the segments analyzed in the report, is expected to record a 17.9% CAGR and reach US$5.1 Billion by the end of the analysis period. Growth in the Single-Cell Multiomics segment is estimated at 14.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$769.1 Million While China is Forecast to Grow at 15.6% CAGR

The Multiomics market in the U.S. is estimated at US$769.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 15.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.5% and 14.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 12.1% CAGR.

Global Multiomics Market - Key Trends & Drivers Summarized

How Is Multiomics Redefining Biological Insights and Precision Medicine?

Multiomics, an integrative approach combining genomics, transcriptomics, proteomics, epigenomics, and metabolomics, is revolutionizing biological research and clinical applications. By leveraging vast datasets across multiple biological layers, multiomics offers a deeper understanding of complex diseases, biological functions, and personalized medicine. Advances in sequencing technologies and high-throughput analytical tools have enabled researchers to study interactions between different molecular components with unprecedented precision. The integration of machine learning and artificial intelligence has further accelerated the interpretation of multiomics data, leading to breakthroughs in biomarker discovery, disease diagnostics, and therapeutic interventions. In oncology, multiomics is uncovering tumor heterogeneity and facilitating more targeted treatment regimens. Similarly, in neurodegenerative diseases, such as Alzheimer’s and Parkinson’s, multiomics enables a systems biology approach to uncover genetic and metabolic underpinnings. The pharmaceutical industry is actively adopting multiomics to enhance drug discovery, optimize clinical trial stratification, and predict patient responses to therapies. The advent of cloud computing and advanced bioinformatics tools has significantly improved the ability to store, analyze, and interpret multiomics data at scale, making it more accessible to researchers worldwide. Governments and healthcare institutions are increasingly funding large-scale multiomics initiatives, recognizing their potential to accelerate translational research. Despite these advancements, the field faces challenges related to data harmonization, standardization, and ethical considerations in data sharing. Nevertheless, with continuous innovation in computational biology and data integration frameworks, multiomics is poised to transform precision medicine and disease prevention strategies.

What Are the Emerging Applications and Industries Benefiting from Multiomics?

Beyond its role in precision medicine, multiomics is finding applications in diverse fields, including agriculture, microbiome research, nutrition science, and environmental monitoring. In agriculture, multiomics is being employed to enhance crop resilience, improve soil microbiomes, and develop genetically superior plant varieties that can withstand climate change-induced stressors. Microbiome research is leveraging multiomics to study complex microbial interactions in human health, agriculture, and industrial biotechnology. The application of metagenomics, proteomics, and metabolomics in gut microbiota studies has led to groundbreaking discoveries linking microbiome composition to diseases such as obesity, diabetes, and inflammatory disorders. In nutrition science, multiomics is paving the way for nutrigenomics, where personalized dietary recommendations are tailored based on an individual’s genetic and metabolic profile. The food and beverage industry is utilizing multiomics to optimize fermentation processes, improve probiotic formulations, and ensure food safety through advanced microbial profiling. Multiomics is also making significant contributions to environmental sciences by enabling researchers to monitor ecosystem biodiversity, track pollution effects, and study microbial communities in extreme environments such as deep-sea hydrothermal vents. The field of toxicology is increasingly integrating multiomics approaches to understand chemical exposures at the molecular level, improving risk assessments and regulatory frameworks. With advancements in synthetic biology, multiomics is facilitating the engineering of novel biomaterials, biofuels, and biopharmaceuticals, further expanding its industrial significance. The increasing interdisciplinary adoption of multiomics underscores its transformative impact across scientific and commercial sectors, driving innovation beyond traditional biomedical research.

Why Is Multiomics Data Integration Critical for Future Scientific Breakthroughs?

The integration of multiomics datasets remains one of the most challenging yet promising aspects of the field. The vast volume of data generated from multiomics studies requires sophisticated computational models capable of synthesizing insights across different biological layers. Recent advancements in AI-driven analytics, federated learning, and network-based modeling have improved multiomics data fusion, leading to more robust biomarker discovery and disease modeling. The standardization of data pipelines and the development of open-access repositories have facilitated greater collaboration among researchers, allowing for meta-analyses and cross-population studies. The emergence of single-cell multiomics has further enhanced resolution in understanding cellular heterogeneity, proving valuable in immunology, cancer biology, and developmental biology. Spatial multiomics is another breakthrough, enabling researchers to map molecular interactions within tissues with spatial precision, offering new insights into disease pathology. However, challenges such as batch effects, reproducibility issues, and the need for enhanced computational infrastructure remain barriers to widespread adoption. The push towards multi-institutional collaborations and data-sharing frameworks is expected to mitigate these challenges, fostering greater reproducibility and transparency in multiomics research. The integration of multiomics with digital twin technologies, where computational models simulate biological responses, is another promising frontier that could revolutionize personalized medicine and therapeutic development. As multiomics continues to evolve, it is increasingly intersecting with other cutting-edge fields such as quantum computing, CRISPR-based genome editing, and bioprinting, opening new avenues for scientific discovery. The ability to seamlessly integrate multiomics data will be crucial in unlocking the full potential of this technology, enabling more accurate predictions of disease trajectories and treatment responses.

What Is Driving the Rapid Growth of the Global Multiomics Market?

The growth in the global multiomics market is driven by several factors, including technological advancements, rising adoption in drug discovery, and increased funding for omics-based research. The rapid development of next-generation sequencing (NGS), mass spectrometry, and high-throughput screening platforms has significantly reduced costs while improving accuracy and scalability. The pharmaceutical and biotechnology industries are heavily investing in multiomics to accelerate precision medicine initiatives, enhance biomarker identification, and optimize clinical trial patient selection. The increasing incidence of complex diseases, including cancer, autoimmune disorders, and neurodegenerative conditions, is further fueling demand for multiomics-driven diagnostics and therapeutics. The integration of multiomics with artificial intelligence and big data analytics is attracting substantial venture capital and government funding, particularly for research focused on rare diseases and personalized healthcare solutions. Regulatory agencies are increasingly recognizing the value of multiomics in improving drug safety and efficacy, leading to favorable policies supporting omics-based clinical trials and companion diagnostics. The rise of direct-to-consumer genetic testing companies and personalized wellness programs is further expanding the commercial landscape for multiomics applications. Moreover, the growing emphasis on multiomics in agriculture, food safety, and environmental monitoring is driving its adoption beyond human health, contributing to market diversification. The emergence of multiomics service providers offering end-to-end solutions, including data analysis, biomarker validation, and cloud-based informatics platforms, is making multiomics research more accessible to academic and industrial researchers alike. Strategic partnerships between multiomics technology developers, healthcare providers, and pharmaceutical companies are fostering innovation, accelerating commercialization, and enhancing translational research efforts. As the global healthcare industry shifts towards preventive and precision-based treatment models, multiomics is set to become an indispensable tool in future healthcare paradigms. With continuous advancements in multiomics technologies and their increasing applications across multiple industries, the market is poised for exponential growth in the coming years.

SCOPE OF STUDY:

The report analyzes the Multiomics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Bulk Multiomics, Single-Cell Multiomics); Platform Type (Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform, Integrated Omics Platforms); Application (Oncology Application, Cell Biology Application, Neurology Application, Immunology Application); End-Use (Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 41 Featured) -

  • 10x Genomics, Inc.
  • Agilent Technologies, Inc.
  • Aitia (formerly GNS Healthcare)
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • Bruker Corporation
  • Danaher Corporation
  • Freenome Holdings, Inc.
  • Human Longevity, Inc.
  • Illumina, Inc.
  • Mission Bio, Inc.
  • NanoString Technologies, Inc.
  • PerkinElmer, Inc.
  • Pleno, Inc.
  • Psomagen, Inc.
  • QIAGEN N.V.
  • Shimadzu Corporation
  • SOPHiA GENETICS
  • Thermo Fisher Scientific Inc.
  • Waters Corporation

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Multiomics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Integration of Multiomics Data Sets Strengthens the Business Case for Precision Medicine
    • Rising Focus on Systems Biology Propels Growth in Multiomics Research
    • Increasing Adoption of Personalized Healthcare Expands the Addressable Market Opportunity
    • Convergence of Genomics, Proteomics, and Metabolomics Accelerates Demand for Integrated Platforms
    • Big Data and AI Capabilities Drive Adoption of Multiomics Analytics
    • Growing Investments in Life Sciences R&D Sustain Growth Momentum
    • Clinical Trials Leveraging Multiomics Approaches Generate New Opportunities in Drug Discovery
    • Advances in Single-Cell Sequencing Technologies Drive Demand for High-Resolution Multiomics
    • Expansion of Population-Scale Biobanking Initiatives Spurs Adoption of Multiomics Technologies
    • Strategic Collaborations Between Biotech and Tech Firms Boost Commercialization Potential
    • Decentralization of Diagnostic Workflows Drives Demand for Scalable Multiomics Platforms
    • Rising Prevalence of Chronic and Complex Diseases Throws the Spotlight on Omics-Based Biomarker Discovery
    • Increased Regulatory Support for Genomic Testing Strengthens the Reimbursement Framework for Multiomics
    • Development of Multiomic Diagnostic Kits Generates Opportunities for Point-of-Care Applications
    • Integration with Electronic Health Records Drives Clinical Utility and Adoption in Hospitals
    • Emergence of Cloud-Native Platforms Expands Accessibility and Scalability for Multiomics Data Processing
    • Improved Cost-Efficiency of Sequencing Technologies Drives Market Penetration in Developing Economies
    • Rising Academic and Government Funding Accelerates Translational Research in Multiomics
    • Growing Emphasis on Real-Time Disease Monitoring Supports Growth of Longitudinal Multiomics Studies
    • Standardization and Interoperability Challenges Create Barriers but Also Spur Innovation in Unified Analytics Frameworks
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Multiomics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Multiomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for Multiomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Bulk Multiomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Bulk Multiomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Single-Cell Multiomics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Single-Cell Multiomics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Neurology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Neurology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Immunology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Immunology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Oncology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Oncology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Cell Biology Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Cell Biology Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Genomics Platform by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 23: World 6-Year Perspective for Genomics Platform by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 24: World Recent Past, Current & Future Analysis for Transcriptomics Platform by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 25: World 6-Year Perspective for Transcriptomics Platform by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Proteomics Platform by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World 6-Year Perspective for Proteomics Platform by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Metabolomics Platform by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 29: World 6-Year Perspective for Metabolomics Platform by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 30: World Recent Past, Current & Future Analysis for Integrated Omics Platforms by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 31: World 6-Year Perspective for Integrated Omics Platforms by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Multiomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Multiomics by Product Type - Bulk Multiomics and Single-Cell Multiomics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA 6-Year Perspective for Multiomics by Product Type - Percentage Breakdown of Value Sales for Bulk Multiomics and Single-Cell Multiomics for the Years 2025 & 2030
    • TABLE 34: USA Recent Past, Current & Future Analysis for Multiomics by Application - Neurology Application, Immunology Application, Oncology Application and Cell Biology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: USA 6-Year Perspective for Multiomics by Application - Percentage Breakdown of Value Sales for Neurology Application, Immunology Application, Oncology Application and Cell Biology Application for the Years 2025 & 2030
    • TABLE 36: USA Recent Past, Current & Future Analysis for Multiomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: USA 6-Year Perspective for Multiomics by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 38: USA Recent Past, Current & Future Analysis for Multiomics by Platform Type - Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA 6-Year Perspective for Multiomics by Platform Type - Percentage Breakdown of Value Sales for Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms for the Years 2025 & 2030
  • CANADA
    • TABLE 40: Canada Recent Past, Current & Future Analysis for Multiomics by Product Type - Bulk Multiomics and Single-Cell Multiomics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: Canada 6-Year Perspective for Multiomics by Product Type - Percentage Breakdown of Value Sales for Bulk Multiomics and Single-Cell Multiomics for the Years 2025 & 2030
    • TABLE 42: Canada Recent Past, Current & Future Analysis for Multiomics by Application - Neurology Application, Immunology Application, Oncology Application and Cell Biology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: Canada 6-Year Perspective for Multiomics by Application - Percentage Breakdown of Value Sales for Neurology Application, Immunology Application, Oncology Application and Cell Biology Application for the Years 2025 & 2030
    • TABLE 44: Canada Recent Past, Current & Future Analysis for Multiomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Canada 6-Year Perspective for Multiomics by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 46: Canada Recent Past, Current & Future Analysis for Multiomics by Platform Type - Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 47: Canada 6-Year Perspective for Multiomics by Platform Type - Percentage Breakdown of Value Sales for Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms for the Years 2025 & 2030
  • JAPAN
    • Multiomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 48: Japan Recent Past, Current & Future Analysis for Multiomics by Product Type - Bulk Multiomics and Single-Cell Multiomics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Japan 6-Year Perspective for Multiomics by Product Type - Percentage Breakdown of Value Sales for Bulk Multiomics and Single-Cell Multiomics for the Years 2025 & 2030
    • TABLE 50: Japan Recent Past, Current & Future Analysis for Multiomics by Application - Neurology Application, Immunology Application, Oncology Application and Cell Biology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Japan 6-Year Perspective for Multiomics by Application - Percentage Breakdown of Value Sales for Neurology Application, Immunology Application, Oncology Application and Cell Biology Application for the Years 2025 & 2030
    • TABLE 52: Japan Recent Past, Current & Future Analysis for Multiomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Japan 6-Year Perspective for Multiomics by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 54: Japan Recent Past, Current & Future Analysis for Multiomics by Platform Type - Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: Japan 6-Year Perspective for Multiomics by Platform Type - Percentage Breakdown of Value Sales for Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms for the Years 2025 & 2030
  • CHINA
    • Multiomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 56: China Recent Past, Current & Future Analysis for Multiomics by Product Type - Bulk Multiomics and Single-Cell Multiomics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: China 6-Year Perspective for Multiomics by Product Type - Percentage Breakdown of Value Sales for Bulk Multiomics and Single-Cell Multiomics for the Years 2025 & 2030
    • TABLE 58: China Recent Past, Current & Future Analysis for Multiomics by Application - Neurology Application, Immunology Application, Oncology Application and Cell Biology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: China 6-Year Perspective for Multiomics by Application - Percentage Breakdown of Value Sales for Neurology Application, Immunology Application, Oncology Application and Cell Biology Application for the Years 2025 & 2030
    • TABLE 60: China Recent Past, Current & Future Analysis for Multiomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: China 6-Year Perspective for Multiomics by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 62: China Recent Past, Current & Future Analysis for Multiomics by Platform Type - Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: China 6-Year Perspective for Multiomics by Platform Type - Percentage Breakdown of Value Sales for Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms for the Years 2025 & 2030
  • EUROPE
    • Multiomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 64: Europe Recent Past, Current & Future Analysis for Multiomics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 65: Europe 6-Year Perspective for Multiomics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 66: Europe Recent Past, Current & Future Analysis for Multiomics by Product Type - Bulk Multiomics and Single-Cell Multiomics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Europe 6-Year Perspective for Multiomics by Product Type - Percentage Breakdown of Value Sales for Bulk Multiomics and Single-Cell Multiomics for the Years 2025 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Multiomics by Application - Neurology Application, Immunology Application, Oncology Application and Cell Biology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Europe 6-Year Perspective for Multiomics by Application - Percentage Breakdown of Value Sales for Neurology Application, Immunology Application, Oncology Application and Cell Biology Application for the Years 2025 & 2030
    • TABLE 70: Europe Recent Past, Current & Future Analysis for Multiomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Europe 6-Year Perspective for Multiomics by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 72: Europe Recent Past, Current & Future Analysis for Multiomics by Platform Type - Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: Europe 6-Year Perspective for Multiomics by Platform Type - Percentage Breakdown of Value Sales for Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms for the Years 2025 & 2030
  • FRANCE
    • Multiomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 74: France Recent Past, Current & Future Analysis for Multiomics by Product Type - Bulk Multiomics and Single-Cell Multiomics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: France 6-Year Perspective for Multiomics by Product Type - Percentage Breakdown of Value Sales for Bulk Multiomics and Single-Cell Multiomics for the Years 2025 & 2030
    • TABLE 76: France Recent Past, Current & Future Analysis for Multiomics by Application - Neurology Application, Immunology Application, Oncology Application and Cell Biology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: France 6-Year Perspective for Multiomics by Application - Percentage Breakdown of Value Sales for Neurology Application, Immunology Application, Oncology Application and Cell Biology Application for the Years 2025 & 2030
    • TABLE 78: France Recent Past, Current & Future Analysis for Multiomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: France 6-Year Perspective for Multiomics by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 80: France Recent Past, Current & Future Analysis for Multiomics by Platform Type - Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: France 6-Year Perspective for Multiomics by Platform Type - Percentage Breakdown of Value Sales for Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms for the Years 2025 & 2030
  • GERMANY
    • Multiomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 82: Germany Recent Past, Current & Future Analysis for Multiomics by Product Type - Bulk Multiomics and Single-Cell Multiomics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Germany 6-Year Perspective for Multiomics by Product Type - Percentage Breakdown of Value Sales for Bulk Multiomics and Single-Cell Multiomics for the Years 2025 & 2030
    • TABLE 84: Germany Recent Past, Current & Future Analysis for Multiomics by Application - Neurology Application, Immunology Application, Oncology Application and Cell Biology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Germany 6-Year Perspective for Multiomics by Application - Percentage Breakdown of Value Sales for Neurology Application, Immunology Application, Oncology Application and Cell Biology Application for the Years 2025 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Multiomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Germany 6-Year Perspective for Multiomics by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 88: Germany Recent Past, Current & Future Analysis for Multiomics by Platform Type - Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Germany 6-Year Perspective for Multiomics by Platform Type - Percentage Breakdown of Value Sales for Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms for the Years 2025 & 2030
  • ITALY
    • TABLE 90: Italy Recent Past, Current & Future Analysis for Multiomics by Product Type - Bulk Multiomics and Single-Cell Multiomics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Italy 6-Year Perspective for Multiomics by Product Type - Percentage Breakdown of Value Sales for Bulk Multiomics and Single-Cell Multiomics for the Years 2025 & 2030
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Multiomics by Application - Neurology Application, Immunology Application, Oncology Application and Cell Biology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Italy 6-Year Perspective for Multiomics by Application - Percentage Breakdown of Value Sales for Neurology Application, Immunology Application, Oncology Application and Cell Biology Application for the Years 2025 & 2030
    • TABLE 94: Italy Recent Past, Current & Future Analysis for Multiomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Italy 6-Year Perspective for Multiomics by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 96: Italy Recent Past, Current & Future Analysis for Multiomics by Platform Type - Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 97: Italy 6-Year Perspective for Multiomics by Platform Type - Percentage Breakdown of Value Sales for Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms for the Years 2025 & 2030
  • UNITED KINGDOM
    • Multiomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 98: UK Recent Past, Current & Future Analysis for Multiomics by Product Type - Bulk Multiomics and Single-Cell Multiomics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: UK 6-Year Perspective for Multiomics by Product Type - Percentage Breakdown of Value Sales for Bulk Multiomics and Single-Cell Multiomics for the Years 2025 & 2030
    • TABLE 100: UK Recent Past, Current & Future Analysis for Multiomics by Application - Neurology Application, Immunology Application, Oncology Application and Cell Biology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 101: UK 6-Year Perspective for Multiomics by Application - Percentage Breakdown of Value Sales for Neurology Application, Immunology Application, Oncology Application and Cell Biology Application for the Years 2025 & 2030
    • TABLE 102: UK Recent Past, Current & Future Analysis for Multiomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 103: UK 6-Year Perspective for Multiomics by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Multiomics by Platform Type - Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: UK 6-Year Perspective for Multiomics by Platform Type - Percentage Breakdown of Value Sales for Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 106: Rest of Europe Recent Past, Current & Future Analysis for Multiomics by Product Type - Bulk Multiomics and Single-Cell Multiomics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 107: Rest of Europe 6-Year Perspective for Multiomics by Product Type - Percentage Breakdown of Value Sales for Bulk Multiomics and Single-Cell Multiomics for the Years 2025 & 2030
    • TABLE 108: Rest of Europe Recent Past, Current & Future Analysis for Multiomics by Application - Neurology Application, Immunology Application, Oncology Application and Cell Biology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 109: Rest of Europe 6-Year Perspective for Multiomics by Application - Percentage Breakdown of Value Sales for Neurology Application, Immunology Application, Oncology Application and Cell Biology Application for the Years 2025 & 2030
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Multiomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Rest of Europe 6-Year Perspective for Multiomics by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 112: Rest of Europe Recent Past, Current & Future Analysis for Multiomics by Platform Type - Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 113: Rest of Europe 6-Year Perspective for Multiomics by Platform Type - Percentage Breakdown of Value Sales for Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms for the Years 2025 & 2030
  • ASIA-PACIFIC
    • Multiomics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 114: Asia-Pacific Recent Past, Current & Future Analysis for Multiomics by Product Type - Bulk Multiomics and Single-Cell Multiomics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 115: Asia-Pacific 6-Year Perspective for Multiomics by Product Type - Percentage Breakdown of Value Sales for Bulk Multiomics and Single-Cell Multiomics for the Years 2025 & 2030
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Multiomics by Application - Neurology Application, Immunology Application, Oncology Application and Cell Biology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific 6-Year Perspective for Multiomics by Application - Percentage Breakdown of Value Sales for Neurology Application, Immunology Application, Oncology Application and Cell Biology Application for the Years 2025 & 2030
    • TABLE 118: Asia-Pacific Recent Past, Current & Future Analysis for Multiomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 119: Asia-Pacific 6-Year Perspective for Multiomics by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 120: Asia-Pacific Recent Past, Current & Future Analysis for Multiomics by Platform Type - Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 121: Asia-Pacific 6-Year Perspective for Multiomics by Platform Type - Percentage Breakdown of Value Sales for Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 122: Rest of World Recent Past, Current & Future Analysis for Multiomics by Product Type - Bulk Multiomics and Single-Cell Multiomics - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of World 6-Year Perspective for Multiomics by Product Type - Percentage Breakdown of Value Sales for Bulk Multiomics and Single-Cell Multiomics for the Years 2025 & 2030
    • TABLE 124: Rest of World Recent Past, Current & Future Analysis for Multiomics by Application - Neurology Application, Immunology Application, Oncology Application and Cell Biology Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 125: Rest of World 6-Year Perspective for Multiomics by Application - Percentage Breakdown of Value Sales for Neurology Application, Immunology Application, Oncology Application and Cell Biology Application for the Years 2025 & 2030
    • TABLE 126: Rest of World Recent Past, Current & Future Analysis for Multiomics by End-Use - Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 127: Rest of World 6-Year Perspective for Multiomics by End-Use - Percentage Breakdown of Value Sales for Academic & Research Institutes End-Use, Pharma & Biotech Companies End-Use and Other End-Uses for the Years 2025 & 2030
    • TABLE 128: Rest of World Recent Past, Current & Future Analysis for Multiomics by Platform Type - Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of World 6-Year Perspective for Multiomics by Platform Type - Percentage Breakdown of Value Sales for Genomics Platform, Transcriptomics Platform, Proteomics Platform, Metabolomics Platform and Integrated Omics Platforms for the Years 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제